GlassScriptPhysician profile
Jean C Buhac
NPI 1720098262
$2,313.47
in general payments reported to CMS, 2019-2025
11 companies · $274 in 2025
The $274 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $278 · 2020: $122 · 2021: $140 · 2022: $775 · 2023: $438 · 2024: $287 · 2025: $274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $862 · Education: $138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $861.55 |
| Education | $137.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $728.69 | 2022-2023 | Xeomin |
| Janssen Biotech, INC. | $603.73 | 2019-2024 | Tremfya |
| Abbvie INC. | $391.96 | 2019-2025 | Skyrizi, Rinvoq |
| Allergan, INC. | $229.64 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $131.16 | 2023-2025 | |
| Revance Therapeutics, INC. | $74.82 | 2024-2025 | Daxxify |
| Galderma Laboratories, L.P. | $49.46 | 2025 | Nemluvio |
| Lilly USA, LLC | $38.93 | 2019 | |
| Arcutis Biotherapeutics, INC. | $32.41 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $17.18 | 2023 | Vtama |
| Amgen INC. | $15.49 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jean Buhac listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.